According to Agomab, the US Patent and Trademark Office (USPTO) has granted a composition of matter patent (US Patent No. 12,577,230) covering the company’s AGMB-447 inhaled ALK5 (TGFβR1) inhibitor through 2041. Agomab is developing AGMB-447 for the treatment of idiopathic pulmonary fibrosis and recently announced interim results from a Phase 1 study of the drug in healthy participants. The FDA awarded orphan drug designation to AGMB-447 for the treatment of IPF in 2024.
Agomab CEO Tim Knotnerus commented, “The issuance of this patent is a significant milestone that solidifies the foundational IP for AGMB-447 in the US. Building a global patent portfolio for AGMB-447 is an important step in our mission to address the high unmet medical need for people living with IPF. Following the positive healthy subject data for AGMB-447, we look forward to the results of the IPF patient cohort of the Phase 1b study later this year.”
Read the Agomab press release
